{'fraction_non_alphanumeric': 0.051560379918588875, 'fraction_numerical': 0.035278154681139755, 'mean_word_length': 4.72093023255814, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Recombinant Microcystis viridis lectin as a potential anticancer agent.

MVL (Microcystis viridis lectin), a glycoprotein originally isolated from freshwater blue-green algae Microcystis viridis, has been reported to have potent anti-HIV activity. However, the objective of this study was to evaluate the anticancer activity of recombinant MVL (R-MVL). MTT assay was used to evaluate the in vitro anticancer activity of R-MVL, and the results show that the IC50 for HT-29, HepG2, SGC-7901 and SK-OV-3 were 40.20, 42.67, 49.87, and 53.40 microg/ml, respectively. Our data, for the first time, demonstrated that R-MVL exhibits potential anticancer activity, and open new therapeutic possibilities for the use of R-MVL as anti-cancer agent.